Dual action antidepressants and some important considerations

References

• Danish University Antidepressant Group Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986; 90: 131–138
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 1990; 18: 289–299
   PubMed Web of Science ®Google Scholar
• Anderson I M, Tomenson B M. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology 1994; 8: 238–249
   PubMed Web of Science ®Google Scholar
• Anderson I M. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression Anxiety 1998; 7(Suppl. 1)11–17
   PubMedGoogle Scholar
• Briley M. The logical evolution towards dual action antidepressants. Drugs in Focus 2001; 3: 5–10
   Google Scholar
• Davis R, Wilde M I. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996; 5: 389–402
   PubMed Web of Science ®Google Scholar
• Stimmel G L, Dopheide J A, Stahl S M. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17: 10–21
   PubMed Web of Science ®Google Scholar
• Kasper S, Praschak-Rieder N, Tauscher J, et al. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Safety 1997; 17: 251–264
   PubMed Web of Science ®Google Scholar
• Kent J M. SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911–918
   PubMed Web of Science ®Google Scholar
• Beique J C, De Montigny C, Blier P, et al. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. British Journal of Pharmacology 1998; 125: 526–532
   PubMed Web of Science ®Google Scholar
• Rudolph R L, Feiger A D. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders 1999; 56: 171–181
   PubMed Web of Science ®Google Scholar
• Thase M E, Nierenberg A A, Keller M B, Panagides J. For the Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. Journal of Clinical Psychiatry 2001; 162: 10
   Google Scholar
• Montgomery S A, Reimitz P E, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled. Psychopharmacology 1998; 13: 63–73
   Web of Science ®Google Scholar
• Bremner J D, Smith W T. Org 3770 vs amitriptyline in the continuation treatment of depression: a placebo-controlled trial. European Journal of Psychiatry 1996; 10: 5
   Web of Science ®Google Scholar
• Shivastava R K, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Journal of Clinical Psychopharmacology 1994; 14: 322–329
   PubMed Web of Science ®Google Scholar
• Entsuah A R, Rudolph R L, Hackett D, Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Clinical Psychopharmacology 1996; 11: 137–145
   PubMed Web of Science ®Google Scholar
• Hackett D, Agniar L, Rudolph R. Venlafaxine prevents recurrence of depression (Poster presentation) Presented at the 11th Congress of the European College of Neuropsychopharmacology. ParisFrance 1998
   Google Scholar
• Rouillon F, Berdeaux G, Bisserbe J C, et al. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. Journal of Affective Disorders 2000; 58: 171–180
   PubMed Web of Science ®Google Scholar
• Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics?. British Journal of Psychiatry 1996; 168: 404–409
   PubMed Web of Science ®Google Scholar
• Pampallona S, Bollini P, Tibaldo G, Kupelnick B, Munizza C. Patient adherence in the treatment of depression. British Journal of Psychiatry 2002; 180: 104–109
   PubMed Web of Science ®Google Scholar
• Moncrieff J. The antidepressant debate. British Journal of Psychiatry 2002; 180: 193–194
   PubMed Web of Science ®Google Scholar
• Montgomery S A, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology 1995; 9: 33–40
   PubMed Web of Science ®Google Scholar
• Thase M E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. Journal of Clinical Psychiatry 1998; 59: 502–508
   PubMed Web of Science ®Google Scholar
• Kasper S, Pletan Y, Solles A, Tourneaux A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. International Clinical Psychopharmacology 1996; 11(Suppl. 4)35–39
   PubMed Web of Science ®Google Scholar
• Holliday S M, Benfield Venlafaxine P. A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280–294
   PubMed Web of Science ®Google Scholar
• Mackay F R, Dunn N R, Martin R M, Pearce G L, Freemantle S N, Mann R D. Newer antidepressants: a comparison of tolerability in general practice. British Journal of General Practice 1999; 49: 892–896
   PubMed Web of Science ®Google Scholar
• Lopez-Ibor J, Guelfi J D, Pletan Y, Tournoux A, Prost J F. Milnacipran and selective serotonin reuptake inhibitors in major depression. International Clinical Psychopharmacology 1996; 11(Suppl. 4)41–46
   PubMed Web of Science ®Google Scholar
• Martin R M, Hilton S R, Kerry S M, Richards N M. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. British Medical Journal 1997; 314: 646–651
   PubMed Web of Science ®Google Scholar
• Troy S, Piergies A, Lucki I, et al. Venlafaxine pharmacokinetics and pharmacodynamics (abstract). Clinical Neuropharmacology 1992; 15(Suppl. 1)234B
   Google Scholar
• Silverstone P H, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. Journal of Clinical Psychiatry 1999; 60: 22–28
   PubMed Web of Science ®Google Scholar
• Fava M. Weight gain and antidepressents. Journal of Clinical Psychiatry 2000; 61(Suppl. 11)37–41
   PubMed Web of Science ®Google Scholar
• Baldwin D S, Birtwistle J. Antidepressant drugs and sexual function: improving the recognition and management of sexual dysfunction in depressed patients. Antidepressant therapy at the dawn of the third millennium, M Briley, S Montgomery. Martin Dunitz, London 1998; 231–253
   Google Scholar
• Rosen R C, Lane R M, Menza M. Effects of SSRIs on sexual function: a critical review. Journal of Clinical Psychopharmacology 1999; 19: 67–85
   PubMed Web of Science ®Google Scholar
• Ernst C, Foldenyi M, Angst J. The Zurich study. XXI. Sexual dysfunction and disturbances in young adults. Data of a longitudinal epidemiological study. European Archives of Psychiatry and Clinical Neurosciences 1993; 243: 179–188
   PubMed Web of Science ®Google Scholar
• Montejo-Gonzales A L, Llorca G, Izquierdo J A, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sex Therapy 1997; 23: 176–194
   PubMed Web of Science ®Google Scholar
• Piazza L A, Markowitz J C, Kocsis J H, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. American Journal of Psychiatry 1997; 54: 1757–1759
   Web of Science ®Google Scholar
• Shen W W, Hsu J H. Female sexual side-effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. International Journal of Psychiatry 1995; 25: 239–248
   Google Scholar
• Mendels J, Camera A, Sikes C. Sertraline treatment for premature ejaculation. Clinical Psychopharmacology 1995; 15: 341–346
   Web of Science ®Google Scholar
• Preskorn S H. Comparison of the tolerability of buproprion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline and venlafaxine. Journal of Clinical Psychiatry 1995; 56: 1221
   Web of Science ®Google Scholar
• Montgomery S A, Prost J F, Solles A, Briley M. Efficacy and tolerability of milnacipran: an overview. International Clinical Psychopharmacology 1996; 11(Suppl. 4)47–51
   PubMed Web of Science ®Google Scholar
• Schatzberg A F, Haddad P, Kaplan E M, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation consensus panel. Journal of Clinical Psychiatry 1997a; 58(Suppl. 7)5–10
   PubMed Web of Science ®Google Scholar
• MacCall C, Callender J. Mirtazapine withdrawal causing hypomania. British Journal of Psychiatry 1999; 175: 390
   PubMed Web of Science ®Google Scholar
• Klesmer J, Sarcevica A, Fomari V. Panic attacks during discontinuation of mirtazepine. Canadian Journal of Psychiatry 2000; 45: 570–571
   PubMed Web of Science ®Google Scholar
• Farah A, Lauer T E. Possible venlafaxine withdrawal syndrome. American Journal of Psychiatry 1996; 153: 576
   PubMed Web of Science ®Google Scholar
• Johnson H, Bouman W P, Lawton J. Withdrawal reaction associated with venlafaxine. British Medical Journal of 1998; 317: 787
   PubMed Web of Science ®Google Scholar
• Parker G, Mitchell P, Wilhelm K, et al. Are the new antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review. Australian and New Zealand Journal of Psychiatry 1999; 33: 874–881
   PubMed Web of Science ®Google Scholar
• Parker G, Hadzi Pavlovic D, Wilhelm K, et al. Defining melancholia: properties of refined sign-based measure. British Journal of Psychiatry 1994; 164: 316–326
   PubMed Web of Science ®Google Scholar
• Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. British Journal of Psychiatry 2001; 178: 129–144
   PubMed Web of Science ®Google Scholar
• Lin K M. Biological differences in depression and anxiety across races, ethnic groups. Journal of Clinical Psychiatry 2001; 62(Suppl. 13)13–19, discussion 20–1
   PubMed Web of Science ®Google Scholar
• Wang J F, Bown C D, Chen B, Young L T. Identification of mood stabilizer-regulated genes by differential-display PCR. International Journal of Neuropsychopharmacology 2001; 4: 65–74
   PubMed Web of Science ®Google Scholar
• Lesch K, Heils A. Serotonergic gene transcriptional control regions: targets for antidepressant drug development?. International Journal of Neuropsychopharmacology 2000; 3: 67–79
   PubMed Web of Science ®Google Scholar
• Cassano G B, Musetti L, Soriani A, Savino M. The Pharmacological treatment of Depression: Drug selection Criteria. Pharmacopsychiatry 1993; 26(Suppl. 1)17–23
   PubMedGoogle Scholar
• Paykel E S, Priest R G. Recognition and management of depression in general practice: consensus statement. British Medical Journal 1992; 305: 1198–1202
   PubMed Web of Science ®Google Scholar
• Kupfer D J, Frank E, Perel J M, et al. Five-year outcome for maintenance therapies in recurrent. Archives of General Psychiatry 1992; 9: 767–773
   Google Scholar